• EQL Pharma will hold its annual general meeting in Lund on Aug. 20, 2026.
• Items include adoption of the financial statements for fiscal 2025/2026 and a proposal to carry forward earnings with no dividend.
• Shareholders will vote on board size, director fees, board and chair elections, and the auditor election.
• The meeting will also vote on the remuneration report and a long-term incentive program via a directed issue of up to 100,000 warrants.
• The warrant plan targets the chief supply chain officer, with each warrant convertible into one new share and an estimated dilution of about 0.34%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202607170415BITN____UKPR__SV_20260717-BIT-9912-0) on July 17, 2026, and is solely responsible for the information contained therein.